Seminars in Oncology
Volume 35 , Pages S1-S2 , June 2008

Introduction

References 

  1. Orr GA, Verdier-Pinard P, McDaid HM, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22:7280–7295
  2. Nogales E. Structural insight into microtubule function. Annu Rev Biophys Biomol Struct. 2001;30:397–420
  3. Wilson L, Jordan MA, Morse A, Margolis R. Interactions of vinblastine with steady-state microtubules in vitro. J Mol Biol. 1982;159:125–149
  4. Jordan MA, Wilson L. Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations. Biochemistry. 1990;29:2730–2739
  5. Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol. 1997;13:83–117
  6. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A. 1993;90:9552–9556
  7. Derry WB, Wilson L, Jordan MA. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry. 1995;34:2203–2211
  8. Correia JJ, Lobert S. Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr Pharm Des. 2001;7:1213–1228
  9. Noble RL, Beer CT, Cutts JH. Further biological activities of vincaleukoblastine-an alkaloid isolated from Vinca rosea (L.). Biochem Pharmacol. 1958;1:347–357
  10. Svoboda GH. Alkaloids of Vinca rosea Linn (IX. Extraction and characterisation of leurosidine and leucocristine). Lloyda. 1961;24:173–178
  11. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents (VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia). J Am Chem Soc. 1971;93:2325–2327
  12. Horwitz SB, Cohen D, Rao S, et al. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;15:55–61
  13. Burkhart CA, Kavallaris M, Horwitz SB. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta. 2001;1471:O1–O9
  14. Kavallaris M, Verrills NM, Hill BT. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist Updat. 2001;4:392–401
  15. Fahy J, Duflos A, Ribet JP, et al. Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc. 1997;119:8576–8577
  16. Kruczynski A, Colpaert F, Tarayre JP, et al. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol. 1998;41:437–447
  17. Hill BT, Fiebig HH, Waud WR, et al. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer. 1999;35:512–520
  18. Lobert S, Ingram JW, Hill BT, et al. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol. 1998;53:908–915
  19. Etievant C, Barret JM, Kruczynski A, et al. Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs. 1998;16:3–17
  20. Etievant C, Kruczynski A, Barret JM, et al. Markedly diminished drug resistance-inducing properties of vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother Pharmacol. 2001;48:62–70

PII: S0093-7754(08)00017-1

doi: 10.1053/j.seminoncol.2008.01.005

Seminars in Oncology
Volume 35 , Pages S1-S2 , June 2008

Article Tools